Common Drug Interactions in ENT: A Review of Antibiotics in Sinusitis
DOI:
https://doi.org/10.52845/JORR/2023/4.3.7Abstract
Abstract
Introduction
Present day medical treatment often involves a polytherapeutic approach whereby patients receive several medications from multiple physicians, thereby risking adverse drug interactions. Checking for possible drug interactions in a busy clinical setting poses a challenge due to the time pressures of modern medical practice. Otolaryngologists and rhinology sub-specialists receive very little education in drug interactions, and easy to use reference materials are not readily available in most ENT offices. In this manuscript, we review potential drug interactions for one of the most commonly prescribed classes of medication that ENT specialists prescribe, antibiotics. We provide a practical reference for general otolaryngologists and rhinologists to utilize in their busy modern day clinical practices.
Methods/Results
Drug interactions for commonly prescribed antibiotics in ENT/rhinology practice were identified using PubMed and Cochrane Library database to search for articles published from inception until December 31, 2022. Full-text articles were reviewed to identify drug combinations that present risk and to identify specific management recommendations to reduce potential harm.
Discussion
Numerous drug-drug interactions exist between antibiotics and other commonly prescribed medications. These interactions can potentially lead to the development of toxic levels of a drug and harm. We provide an easily accessible summary of these interactions and management considerations that would allow ENTs/rhinologists to screen for these potential sources of harm in their busy clinical practices.
References
Di Mizio G, Marcianò G, Palleria C, et al. Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications. Int J Environ Res Public Health. Dec 8 2021;18(24)doi:10.3390/ijerph182412936
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. May 2015;175(5):827-34. doi:10.1001/jamainternmed.2015.0324
Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107-21. doi:10.2165/00003088-200342020-00001
Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open. Mar 24 2016;6(3):
e010989. doi:10.1136/bmjopen-2015-010989
Lees KA, Orlandi RR, Oakley G, Alt JA. The Role of Macrolides and Doxycycline in Chronic Rhinosinusitis. Immunol Allergy Clin North Am. May 2020;40(2):303-315.doi:10.1016/j.iac.2019.
005
Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med. Jun 1997;182(2):115-24. doi:10.1620/tjem.182.115
Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. Feb 2006;116(2):189-93. doi:10.1097/01.mlg.0000191560.53555.08
Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H. A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology. Mar 2009;47(1):66-71.
Suzuki H, Ikeda K, Honma R, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec. May-Jun 2000;62(3):121-7. doi:10.1159/000027731
Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. Nov 2008;122(5):961-8. doi:10.1016/j.jaci.2008.07.008
Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. Sep 2009;124(3):478-84, 484.e1-2. doi:10.1016/j.jaci.2009.05.017
Haxel BR, Clemens M, Karaiskaki N, Dippold U, Kettern L, Mann WJ. Controlled trial for long-term low-dose erythromycin after sinus surgery for chronic rhinosinusitis. Laryngoscope. May 2015;125(5):1048-55. doi:10.1002/lary.25052
Amali A, Saedi B, Rahavi-Ezabadi S, Ghazavi H, Hassanpoor N. Long-term postoperative azithromycin in patients with chronic rhinosinusitis: A randomized clinical trial. Am J Rhinol Allergy. Nov-Dec 2015;29(6):421-4. doi:10.2500/ajra.2015.29.4244
LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol. Jul 1983;72(1):34-9. doi:10.1016/0091-6749(83)90049-0
Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. Jun 18 2013;158(12):869-76. doi:10.7326/0003-4819-158-12-201306180-00004
Lund M, Svanström H, Pasternak B, Hviid A, Melbye M. Concomitant use of statins and macrolide antibiotics and risk of serious renal events: A nationwide cohort study. Int J Cardiol. Oct 15 2018;269:310-316. doi:10.1016/j.ijcard.2018.06.110
Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis. Allergy. Jan 2004;59(1):54-60. doi:10.1046/j.1398-9995.2003.00364.x
Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. May 2010;125(5):1069-1076.e4. doi:10.1016/j.jaci.2010.02.020
Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med. Jul 14 1997;157(13):1421-8.
Sundberg L, Edén T, Ernstson S. Penetration of doxycycline in respiratory mucosa. Acta Otolaryngol. Nov-Dec 1983;96(5-6):501-8. doi:10.3109/00016488309132737
Lawson DH, Jick H. Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci. Jan-Feb 1978;275(1):53-7. doi:10.1097/00000441-197801000-00005
Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. Feb 24 2003;163(4):402-10. doi:10.1001/archinte.163.4.402
Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. Cmaj. Nov 8 2011;183(16):1851-8. doi:10.1503/cmaj.111152
Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. Jun 28 2010;170(12):1045-9. doi:10.1001/archinternmed.2010.142
Marinella M. Severe Hyperkalemia Associated with Trimethoprim-Sulfamethoxazole and Spironolactone. Infectious Diseases in Clinical Practice. 1997;6(4):256-258.
Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. Jun 2012;30(3):e156-66. doi:10.1111/j.1755-5922.2010.00258.x
Roustit M, Blondel E, Villier C, Fonrose X, Mallaret MP. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother. Apr 2010;44(4):764-7. doi:10.1345/aph.1M597
Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. Dicp. Mar 1990;24(3):250-1. doi:10.1177/106002809002400307
Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. Nov 2008;84(5):581-8. doi:10.1038/clpt.2008.150
Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med. Apr 12 2010;170(7):617-21. doi:10.1001/archinternmed.2010.37
Kosoglou T, Rocci ML, Jr., Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin Pharmacol Ther. Oct 1988;44(4):467-77. doi:10.1038/clpt.
181
Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci. Jan 2006;95(1):25-36. doi:10.1002/jps.20536
Katchamart W, Bourré-Tessier J, Donka T, et al. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol. Jul 2010;37(7):1422-30. doi:10.3899/jrheum.090978
Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. Jan 2004;130(1 Suppl):1-45. doi:10.1016/j.otohns.2003.12.003
Höffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. Jun 1985;4(3):345. doi:10.1007/bf02013667
Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med. Nov 30 1989;87(5a):76s-81s. doi:10.1016/0002-9343(89)90028-4
Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. Jama. Sep 1 2015;314(9):926-39. doi:10.1001/jama.2015.7544
Murphy P, Bistas K, Le J. Clindamycin. StatPearls Publishing. 2023.
Dhawan VK, Thadepalli H. Clindamycin: a review of fifteen years of experience. Rev Infect Dis. Nov-Dec 1982;4(6):1133-53. doi:10.1093/clinids/4.6.1133
Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. Apr 2015;152(2 Suppl):S1-s39. doi:10.1177/0194599815572097
Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet. Apr 1993;24(4):289-300. doi:10.2165/00003088-199324040-00003
Ding Y, Jia YY, Li F, et al. The effect of staggered administration of zinc sulfate on the pharmacokinetics of oral cephalexin. Br J Clin Pharmacol. Mar 2012;73(3):422-7. doi:10.1111/j.1365-2125.2011.04098.x
Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms. J Antimicrob Chemother. Feb 1 2018;73(2):265-279. doi:10.1093/jac/dkx351
Rashid K, Khan Y, Ansar F, Waheed A, Aizaz M. Potential Drug-Drug Interactions in Hospitalized Medical Patients: Data From Low Resource Settings. Cureus. Aug 2021;13(8):e17336. doi:10.7759/cureus.17336
